GlassScriptPhysician profile
Cara J Wise
NPI 1851559363
$3,965.49
in general payments reported to CMS, 2019-2025
27 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $439 · 2023: $1,127 · 2024: $989 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647 · Consulting Fee: $500 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.40 |
| Consulting Fee | $500.00 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.47 | 2021-2025 | |
| Journey Medical Corporation | $518.29 | 2025 | |
| Janssen Biotech, INC. | $395.59 | 2022-2025 | Tremfya |
| Amgen INC. | $258.38 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $239.89 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $237.74 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $224.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $211.25 | 2022-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $193.54 | 2024-2025 | |
| Leo Pharma INC. | $180.45 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $148.91 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $111.91 | 2023-2025 | Absorica Ld, Winlevi |
| Genzyme Corporation | $90.04 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Galderma Laboratories, L.P. | $64.04 | 2024-2025 | Nemluvio, Aklief |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $63.48 | 2023-2024 | Zoryve |
| Biofrontera INC. | $60.25 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $58.29 | 2023-2024 | Vtama |
| Almirall LLC | $47.96 | 2021-2022 | |
| Genentech USA, INC. | $43.85 | 2022 | |
| Allergan, INC. | $27.41 | 2021 | |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Organon LLC | $24.58 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2023 | Spevigo |
| Dermira, INC. | $18.16 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.21 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.45 | 2025 | Jublia, Cabtreo, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.